长风药业(02652)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02652 长风药业

交易中 09-03 11:51:32

11.900

-0.800

-6.30%

最高12.800	最低11.750	成交量126.93万
今开12.720	昨收12.700	日振幅8.27%
总市值51.41亿	流通市值38.44亿	总股本4.32亿
成交额1,551万	换手率0.39%	流通股本3.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02652","market":"HK","secType":"STK","nameCN":"长风药业","latestPrice":11.9,"timestamp":1788407476395,"preClose":12.7,"halted":0,"volume":1269300,"delay":0,"changeRate":-0.06299212598425188,"floatShares":323000000,"shares":432000000,"eps":0.007704891189271851,"marketStatus":"交易中","change":-0.8,"latestTime":"09-03 11:51:32","open":12.72,"high":12.8,"low":11.75,"amount":15510108,"amplitude":0.082677,"askPrice":11.9,"askSize":3800,"bidPrice":11.89,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.019995360043916405,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1788408000000},"marketStatusCode":2,"adr":0,"listingDate":1759852800000,"exchange":"SEHK","adjPreClose":12.7,"openAndCloseTimeList":[[1788399000000,1788408000000],[1788411600000,1788422400000]],"volumeRatio":0.693769,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02652","defaultTab":"news","newsList":[{"id":"2663096940","title":"长风药业(02652)发布中期业绩，收益2.1亿元，同比增长2.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663096940","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663096940?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:58","pubTimestamp":1788184711,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 发布2026年中期业绩，收益2.10亿元，同比增长2.1%，主要由于因集团 CF017产品在中东的客户基础及市场覆盖范围持续扩大，CF017产生的收益增加。商业化方面，报告期间集团已上市产品的市场表现受到政策安排、采购周期切换及渠道因素共同影响。报告期间，集团多个鼻科及呼吸产品取得监管进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489912.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662926130","title":"长风药业(02652)完成发行2174.77万股新H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662926130","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662926130?lang=zh_cn&edition=full","pubTime":"2026-08-28 23:43","pubTimestamp":1787931830,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业(02652)发布公告，于2026年8月6日根据一般授权配发及发行2174.77万股新H股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172000579","title":"长风药业：配发及发行21,747,700股H股 占已发行股本约7.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172000579","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172000579?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:16","pubTimestamp":1787926563,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司于2026年8月28日发布公告，称公司根据2026年7月31日签署的配售协议，并依据一般授权配发及发行21,747,700股新H股。该次新股发行变动日期为2026年8月6日，发行股份数量占此前已发行股份总数的约7.23%，每股发行价为13.82港元。发行完成后，公司已发行股份增至322,574,286股，库藏股数维持1,397,000股，发行人已发行股份总数为323,971,286股。长风药业确认，相关股份发行已符合香港联合交易所有限公司的上市规则以及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"长风药业：配发及发行21,747,700股H股 占已发行股本约7.23%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662721758","title":"港股异动 | 长风药业(02652.HK)盘中拉升逾20% ICF001再获两项临床许可 产品长效吸入前药设计逻辑优势显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2662721758","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662721758?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:06","pubTimestamp":1787796377,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662072173","title":"港股异动 | 长风药业(02652)盘中拉升逾20% ICF001再获两项临床许可 产品长效吸入前药设计逻辑优势显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2662072173","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662072173?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:06","pubTimestamp":1787796377,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，长风药业盘中拉升逾20%，截至发稿，涨6.14%，报16.2港元，成交额5831.08万港元。消息面上，近日，长风药业宣布，集团自主研发的长效吸入干粉候选药物ICF001已获国家药监局就间质性肺病开展临床试验的默示许可。至此，ICF001实现PAH、PH-ILD、IPF、PPF四大适应症全覆盖。ICF001为肺部靶向前药制剂，长效吸入前药设计逻辑优势显著，此次新增两项新适应症临床研究将极大提升临床价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","BK4585","02652","BK1191","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662831200","title":"港股异动 | 长风药业(02652)涨超5% ICF001实现IPF/PPF等四大适应症全覆盖 规划同步启动境内外I期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2662831200","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662831200?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:46","pubTimestamp":1787622363,"startTime":"0","endTime":"0","summary":"长风药业(02652)涨超5%，截至发稿，涨5.46%，报16.06港元，成交额650.2万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260825/20260825094640_68825.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260825/20260825094640_68825.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02652","BK1191","BK4585","BK4588","KCAI","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279454","title":"重大突破！长风药业(02652)ICF001再获两项临床许可 实现IPF/PPF等四大适应症全覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279454","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661279454?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:54","pubTimestamp":1787576046,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，长风药业宣布，集团自主研发的长效吸入干粉候选药物ICF001已获国家药监局就间质性肺病开展临床试验的默示许可。至此，ICF001 实现PAH、PH-ILD、IPF、PPF 四大适应症全覆盖，产品定位与全球最新一代长效吸入前药研发方向高度对标，为公司后续全球多中心临床布局、注册策略规划、海外战略合作筑牢监管基础。ICF001 为肺部靶向前药制剂，长效吸入前药设计逻辑优势显著，此次新增两项新适应症临床研究将极大提升临床价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"重大突破！长风药业(02652)ICF001再获两项临床许可 实现IPF/PPF等四大适应症全覆盖","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119537580","title":"长风药业（02652）长效吸入干粉候选药物ICF001获批扩展IPF及PPF临床试验适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1119537580","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119537580?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:41","pubTimestamp":1787571672,"startTime":"0","endTime":"0","summary":"香港－2026年8月24日，长风药业股份有限公司发布自愿公告称，其自主研发的长效吸入干粉候选药物ICF001已获国家药品监督管理局就间质性肺病中两项适应症——特发性肺纤维化及进行性肺纤维化的临床试验默示许可。至此，ICF001已获准在肺动脉高压、间质性肺病相关肺高压、IPF及PPF四个适应症开展临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659180192","title":"港股午评|恒生指数早盘涨0.07%      医药板块涨幅领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2659180192","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659180192?lang=zh_cn&edition=full","pubTime":"2026-08-13 12:00","pubTimestamp":1786593618,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.07，涨17点，报25457点；恒生科技指数涨0.30%。港股早盘成交1320亿港元。恒生创新药指数涨超2.6%；恒生生物科技指数涨超2.5%；其中，派格生物医药-B涨超8%；君实生物涨超7%；石药集团涨超5%。耐世特绩后涨超11%，中期权益持有人应占溢利同比增长35.17% ，正式推出HMDD。智谱涨超5%，获纳入MSCI中国指数，将于本月底生效；MINIMAX-W再涨超6%，近日正式入通并获纳入香港交易所科技100等指数。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00325","HHImain","LU0593848301.USD","SGXZ23171101.USD","LU0417516738.SGD","02513","03296","002565","03115","07500","BK1213","BK1501","300408","SG9999001903.USD","LU0417516571.SGD","BK1509","BK0222","BK0028","HSI","LU0211977185.USD","SG9999000475.SGD","BK1602","BK1589","09115","LU0227179875.USD","BK1170","601600","LU0572940350.SGD","LU0348783233.USD","LU1282649067.USD","LU0488056044.USD","LU0540923850.HKD","LU1808992512.USD","LU0251143458.SGD","SG9999004311.SGD","BK1614","513600","LU0607220059.USD","LU0702159343.USD","LU2039709279.SGD","LU2065171311.SGD","LU0348767384.USD","LU1880383366.USD","01910","LU1813983027.USD","HSTECH","LU0702159699.USD","LU1823568750.SGD","82800","BK1175","00100","03037","LU0384037296.USD","LU0634319403.HKD","BK1193","BK1568","LU2065171402.SGD","02652","BK1169","00522","LU0348784397.USD","LU1282649141.HKD","LU1328277881.USD","LU1235294995.USD","IE0008369823.USD","BK1500","LU0348766576.USD","SG9999004303.SGD","LU1282649810.SGD","LU0348735423.USD","LU1166156734.SGD","BK1253","BK1155","BK1592","01316","BK1117","LU2065169927.USD","LU0011963245.USD","BK1144","02800","BK1513","83115","08279","MCHmain","HK0000286598.CNH","07300","SG9999011746.SGD","603296","LU0274383008.USD","MCHS","07200","01126","BK1577","LU0149534421.HKD","BK1191","02600","LU0648948544.HKD","ASMVY","LU0264606111.USD","03419","LU2065170008.USD","LU1046421795.USD","BK1227","06951","LU0823040885.USD","02833","LU0348825331.USD","SG9999000459.SGD","LU0314109678.HKD","LU0417516902.SGD","LU0572939691.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659218067","title":"长风药业午前涨超5% 完成配售2174.77万股新H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2659218067","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659218067?lang=zh_cn&edition=full","pubTime":"2026-08-13 11:50","pubTimestamp":1786593000,"startTime":"0","endTime":"0","summary":"模拟交易客户端长风药业午前涨超5%，截至发稿，股价上涨5.15%，现报16.94港元，成交额8531.80万港元。长风药业发布公告，已于2026年8月6日完成配售2174.77万股新H股，配售价每股H股13.82港元，净筹约2.95亿港元。据此前公司公告披露，其中净筹款项约70%用于集团创新候选药物的临床及临床前开发；约15%用于在全球范围内开发集团的复杂吸入制剂产品的CMC研究、临床研究、给药装置开发以及注册及监管申报开支。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-13/doc-ininctaw3431193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659187432","title":"港股异动 | 长风药业(02652.HK)涨超5% 完成配售2174.77万股新H股 ICF001有望填补治疗PH-ILD临床空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2659187432","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659187432?lang=zh_cn&edition=full","pubTime":"2026-08-13 11:06","pubTimestamp":1786590384,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167531376","title":"长风药业完成2.95亿港元H股配售 进一步强化研发资金储备","url":"https://stock-news.laohu8.com/highlight/detail?id=1167531376","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167531376?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:15","pubTimestamp":1786018545,"startTime":"0","endTime":"0","summary":"2026年8月6日，长风药业股份有限公司公告称，公司已按每股13.82港元完成21,747,700股新H股配售，所有条件均已达成。此次配售募集总额约3.01亿元港元，扣除佣金及相关费用后的净额约2.95亿元港元，对应每股净发行价约13.56港元。配售股份占扩大后已发行H股约6.74%，占公司已发行股份总数约5.03%。承配人为不少于6名的独立第三方，配售后无承配人成为公司主要股东。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657396006","title":"长风药业(02652.HK)完成配售2174.77万股新H股 净筹约2.95亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657396006","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657396006?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:13","pubTimestamp":1786018389,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161928649","title":"长风药业公布7月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1161928649","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161928649?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:55","pubTimestamp":1785833749,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司于2026年8月4日发布截至2026年7月31日的证券变动月报表。报告显示，公司本月无注册股本变动，注册股本合计人民币411,978,387元。根据公告，长风药业H股本月期初与期末均保持302,223,586股，其中300,826,586股为已发行股份，1,397,000股为库存股份。内资股则维持109,754,801股，与上月相比并无增减变化。据月报表披露，长风药业表示各项证券发行及股份相关事宜均遵守《香港联合交易所有限公司证券上市规则》及其他相关法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655333668","title":"港股异动 | 长风药业(02652.HK)大涨近24% 拟配股净筹约2.95亿用于创新候选药物临床开发等","url":"https://stock-news.laohu8.com/highlight/detail?id=2655333668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655333668?lang=zh_cn&edition=full","pubTime":"2026-07-31 09:55","pubTimestamp":1785462937,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655876382","title":"长风药业(02652)拟配售2174.77万股新H股 净筹约2.95亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655876382","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655876382?lang=zh_cn&edition=full","pubTime":"2026-07-31 07:00","pubTimestamp":1785452432,"startTime":"0","endTime":"0","summary":"配售股份相当于已发行H股约7.23%及已发行股份总数约5.30%，并相当于因配售股份配发及发行而扩大后的已发行H股约6.74%及已发行股份总数约5.03%。假设所有配售股份获悉数配售，配售所得款项总额及所得款项净额预期分别约为3.01亿港元及约2.95亿港元。按此基准，每股配售股份的净发行价将约为13.56港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152823626","title":"长风药业（02652）拟折让约12%配售2,174.77万股H股 预计募资约3.01亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152823626","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152823626?lang=zh_cn&edition=full","pubTime":"2026-07-31 06:55","pubTimestamp":1785452144,"startTime":"0","endTime":"0","summary":"7月31日，长风药业股份有限公司公告称，公司已与中信里昂证券、建银国际金融、天泽证券及新百利融资等配售代理签订配售协议，将按每股13.82港元的价格，向不少于6名承配人配售2,174.77万股新H股。此次配售股份占公司已发行H股约7.23%、占已发行股份总数约5.30%；配售完成后，占扩大后已发行H股约6.74%、占扩大后已发行股份总数约5.03%。配售价较7月30日H股收市价15.70港元折让约11.97%，较前五个交易日平均收市价15.732港元折让约12.15%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146122954","title":"长风药业更新6月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1146122954","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146122954?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:53","pubTimestamp":1783414404,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司于2026年7月7日发布2026年6月股份变动月报表。报告显示，截至2026年6月底，公司注册股本合计为人民币411,978,387元，已发行股份总数维持在302,223,586股不变。公司在2025年12月16日购回181,000股H股并相应将其转入库藏，因此本月已发行H股较上月减少181,000股。内资股方面，已发行及库藏数量均保持109,754,801股不变，未有增减。公告由执行董事及联席公司秘书朱玉玉签署。根据月报所示，截至6月末，公司总股本保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645788880","title":"长风药业(02652)：变更每手买卖单位为100股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645788880","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645788880?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:53","pubTimestamp":1782136392,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业(02652)发布公告，其H股(H股)于香港联合交易所有限公司(联交所)买卖的每手买卖单位将由500股H股更改为100股H股，自2026年7月14日(星期二)上午九时正起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114436002","title":"长风药业回购6,500股股份，耗资约11.81万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114436002","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114436002?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:11","pubTimestamp":1781608303,"startTime":"0","endTime":"0","summary":"长风药业于2026年6月16日公告，基于董事会授权，公司于当日通过香港联合交易所场内回购6,500股H股股份，约占该公司现有已发行股本的0.0022%。回购价格介乎每股18.08港元至18.35港元，合计耗资约118,135港元。回购完成后，公司已发行股本由原先的300,833,086股降至300,826,586股，同时库藏股由1,390,500股增至1,397,000股，总股本仍为302,223,586股。公司确认，此次股份购回已遵守上市规则及相关法律规定。该公司后续将在合规框架下继续执行相关股份事务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长风药业回购6,500股股份，耗资约11.81万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cfpharmtech.com","stockEarnings":[{"period":"1week","weight":-0.1705},{"period":"1month","weight":-0.2547},{"period":"3month","weight":-0.3713},{"period":"6month","weight":-0.6271},{"period":"1year","weight":-0.139},{"period":"ytd","weight":-0.6371}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0023},{"period":"6month","weight":-0.0173},{"period":"1year","weight":-0.0073},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"长风药业股份有限公司是一家主要从事呼吸系统药物及其他相关医疗产品的研发、生产及销售的中国公司。该公司的产品组合主要针对呼吸系统疾病，包括哮喘、慢性阻塞性肺病（COPD）和过敏性鼻炎。该公司主要产品包括CF017，即治疗支气管哮喘的吸入用布地奈德混悬液，以及CF018，一种用于治疗过敏性鼻炎的氮䓬斯汀氟替卡松鼻喷雾剂。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"长风药业","nameEN":"CF PHARMTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长风药业(02652)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长风药业(02652)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长风药业,02652,长风药业股票,长风药业股票老虎,长风药业股票老虎国际,长风药业行情,长风药业股票行情,长风药业股价,长风药业股市,长风药业股票价格,长风药业股票交易,长风药业股票购买,长风药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长风药业(02652)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长风药业(02652)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}